Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

Biochemical and Biophysical Research Communications

Volumn 443, Issue 3, 2014, Pages 828-833

  Kodera, Ryo ^a   Shikata, Kenichi ^a,b   Takatsuka, Tetsuharu ^b   Oda, Kaori ^b   Miyamoto, Satoshi ^b   Kajitani, Nobuo ^b   Hirota, Daisho ^b   Ono, Tetsuichiro ^b   Usui, Hitomi Kataoka ^b   Makino, Hirofumi ^b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Dipeptidyl peptidase 4 inhibitor; Inflammation; Macrophage

Indexed keywords

ALBUMIN; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PKF 275 055; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; CYCLIC AMP URINE LEVEL; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DOWN REGULATION; FOOD INTAKE; GLOMERULUS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; KIDNEY MASS; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINARY EXCRETION;

RATTUS;

C-REACTIVE PROTEIN; CAMP; CD; CLUSTER OF DIFFERENTIATION; CRP; CYCLIC AMP; DIABETIC NEPHROPATHY; DIPEPTIDYL PEPTIDASE-4; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; DPP-4; GASTRIC INHIBITORY POLYPEPTIDE; GIP; GLP-1; GLUCAGON-LIKE PEPTIDE-1; ICAM-1; IL; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN; MACROPHAGE; NF-ΚB; NUCLEAR FACTOR-ΚB; PAM; PERIODIC ACID-METHENAMINE SILVER; SD; SPRAGUE-DAWLEY; TGF-Β; TNF-Α; TRANSFORMING GROWTH FACTOR-Β; TUMOR NECROSIS FACTOR-Α;

ADAMANTANE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; NITRILES; PROTECTIVE AGENTS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84893704282     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.12.049     Document Type: Article

References (25)

1. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions Am. J. Kidney Dis. 34 1999 795 808
2. J.F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros de Fuentes, and J. Garcia-Perez Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy Nat. Rev. Nephrol. 7 2011 327 340
3. J. Wada, and H. Makino Inflammation and the pathogenesis of diabetic nephropathy Clin. Sci. (Lond.) 124 2013 139 152
4. S. Okada, K. Shikata, M. Matsuda, D. Ogawa, H. Usui, Y. Kido, R. Nagase, J. Wada, Y. Shikata, and H. Makino Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes Diabetes 52 2003 2586 2593
5. H.K. Usui, K. Shikata, M. Sasaki, S. Okada, M. Matsuda, Y. Shikata, D. Ogawa, Y. Kido, R. Nagase, K. Yozai, S. Ohga, A. Tone, J. Wada, M. Takeya, S. Horiuchi, T. Kodama, and H. Makino Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation Diabetes 56 2007 363 372
6. K. Yozai, K. Shikata, M. Sasaki, A. Tone, S. Ohga, H. Usui, S. Okada, J. Wada, R. Nagase, D. Ogawa, Y. Shikata, and H. Makino Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions J. Am. Soc. Nephrol. 16 2005 3326 3338
7. B.P. Bullock Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968 2978
8. R. Kodera, K. Shikata, H.U. Kataoka, T. Takatsuka, S. Miyamoto, M. Sasaki, N. Kajitani, S. Nishishita, K. Sarai, D. Hirota, C. Sato, D. Ogawa, and H. Makino Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes Diabetologia 54 2011 965 978
9. T.B. Usdin, E. Mezey, D.C. Button, M.J. Brownstein, and T.I. Bonner Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology 133 1993 2861 2870
10. H. Hendarto, T. Inoguchi, Y. Maeda, N. Ikeda, J. Zheng, R. Takei, H. Yokomizo, E. Hirata, N. Sonoda, and R. Takayanagi GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases Metabolism 61 2012 1422 1434
11. C.W. Park, H.W. Kim, S.H. Ko, J.H. Lim, G.R. Ryu, H.W. Chung, S.W. Han, S.J. Shin, B.K. Bang, M.D. Breyer, and Y.S. Chang Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice J. Am. Soc. Nephrol. 18 2007 1227 1238
12. A. Mima, J. Hiraoka-Yamomoto, Q. Li, M. Kitada, C. Li, P. Geraldes, M. Matsumoto, K. Mizutani, K. Park, C. Cahill, S. Nishikawa, C. Rask-Madsen, and G.L. King Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes Diabetes 61 2012 2967 2979
13. W.J. Liu, S.H. Xie, Y.N. Liu, W. Kim, H.Y. Jin, S.K. Park, Y.M. Shao, and T.S. Park Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats J. Pharmacol. Exp. Ther. 340 2012 248 255
14. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 46 2003 2774 2789
15. A. Tone, K. Shikata, M. Sasaki, S. Ohga, K. Yozai, S. Nishishita, H. Usui, R. Nagase, D. Ogawa, S. Okada, Y. Shikata, J. Wada, and H. Makino Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats Diabetologia 48 2005 2402 2411
16. H. Sugimoto, K. Shikata, K. Hirata, K. Akiyama, M. Matsuda, M. Kushiro, Y. Shikata, N. Miyatake, M. Miyasaka, and H. Makino Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation Diabetes 46 1997 2075 2081
17. J.S. Fong, and K.N. Drummond Method for preparation of glomeruli for metabolic studies J. Lab. Clin. Med. 71 1968 1034 1039
18. N. Ervinna, T. Mita, E. Yasunari, K. Azuma, R. Tanaka, S. Fujimura, D. Sukmawati, T. Nomiyama, A. Kanazawa, R. Kawamori, Y. Fujitani, and H. Watada Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice Endocrinology 154 2013 1260 1270
19. S. Hattori Sitagliptin reduces albuminuria in patients with type 2 diabetes Endocr. J. 58 2011 69 73
20. C. Mega, E.T. de Lemos, H. Vala, R. Fernandes, J. Oliveira, F. Mascarenhas-Melo, F. Teixeira, and F. Reis Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat) Exp. Diabetes Res. 2011 2011 162092
21. M. Yu, C. Moreno, K.M. Hoagland, A. Dahly, K. Ditter, M. Mistry, and R.J. Roman Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J. Hypertens. 21 2003 1125 1135
22. K. Hirata, S. Kume, S. Araki, M. Sakaguchi, M. Chin-Kanasaki, K. Isshiki, T. Sugimoto, A. Nishiyama, D. Koya, M. Haneda, A. Kashiwagi, and T. Uzu Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model Biochem. Biophys. Res. Commun. 380 2009 44 49
23. J.E. Foley, and J. Jordan Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience Vasc. Health Risk Manag. 6 2010 541 548
24. R.O. Crajoinas, F.T. Oricchio, T.D. Pessoa, B.P. Pacheco, L.M. Lessa, G. Malnic, and A.C. Girardi Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1 Am. J. Physiol. Renal Physiol. 301 2011 F355 363
25. R. Mentlein Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9 24